tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Medpace downgraded to Neutral from Buy at Rothschild & Co Redburn

Rothschild & Co Redburn downgraded Medpace (MEDP) to Neutral from Buy with a price target of $474, up from $342. The firm cites valuation for the downgrade following the stock’s recent rally.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1